Market Overview

Noble Financial Initiates Heron Therapeutics At Buy

Conkwest Appoints Robert Rosen And Henry Ji To Its Board Of Directors
Benzinga's Top Initiations

Noble Financial initiated coverage on shares of Heron Therapeutics (NASDAQ: HRTX) with a Buy rating.

The target price for Heron Therapeutics is set to $18.

Heron Therapeutics shares have declined 8.26% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Heron Therapeutics' shares dropped 1.17% to close at $8.44 yesterday.

Latest Ratings for HRTX

Mar 2015JefferiesInitiates Coverage onBuy
Mar 2015Leerink SwannMaintainsOutperform
Aug 2014Noble FinancialInitiates Coverage onBuy

View More Analyst Ratings for HRTX
View the Latest Analyst Ratings

Posted-In: Noble FinancialInitiation Analyst Ratings


Related Articles (HRTX)

Around the Web, We're Loving...